Aminolevulinic Acid

Brand names: Ameluz · Active ingredient: Aminolevulinic Acid Hydrochloride

In short: AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED® or RhodoLED® XL lamp, a narrowband, red light illumination source, is indicated for: lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp in adults. the tre

Forms & strengthsTopical gel: 10% aminolevulinic acid hydrochloride as a white-to-yellowish gel in 2-gram tubes.
LabelBiofrontera Inc.
Label updatedOct 16, 2026

What is Aminolevulinic Acid used for?

AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED® or RhodoLED® XL lamp, a narrowband, red light illumination source, is indicated for:

lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp in adults.

the treatment of superficial basal cell carcinoma (sBCC) in adults.

Aminolevulinic Acid dosage

AMELUZ, in conjunction with lesion preparation, is only to be administered by a healthcare provider.

AMELUZ is for topical use only. Not for ophthalmic, oral, or intravaginal use. Avoid using AMELUZ on the eyelid or around the eye .

AMELUZ treatment, in combination with photodynamic therapy (PDT), is a multi-stage process that requires administration of both AMELUZ and BF-RhodoLED or RhodoLED XL light.

Refer to BF-RhodoLED or RhodoLED XL user manual for detailed lamp safety and operating instructions. Adhere to all safety instructions for both patient and medical personnel while conducting the PDT.

For treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp: Treat single AK lesions or an entire field affected by multiple AK lesions. Retreat AK lesions that have not completely resolved approximately 3 months after the initial treatment.

For treatment of superficial basal cell carcinoma (sBCC): Treat one or multiple sBCC lesions with AMELUZ, in combination with PDT, in two sessions spaced 1 to 2 weeks apart. Approximately 3 months after the initial treatment, retreat lesions that have not completely resolved with AMELUZ, in combination with PDT, in two additional sessions, spaced 1 to 2 weeks apart. Perform a follow-up examination 4 to 6 weeks after each treatment cycle to confirm complete response and perform routine skin examinations every 6 to 12 months.

Apply an approximately 1 mm thick layer of AMELUZ to skin lesion(s). Cover individual lesions (sBCC or AK) or the entire AK field with AMELUZ. Include approximately 5 mm to 10 mm of the surrounding skin. Do not exceed an application area of 60 cm2. Do not use more than 6 grams of AMELUZ (3 tubes) at one time.

AMELUZ treatment, in combination with PDT, is a multi-stage process:

Step 1. Preparation of Lesions

Before applying AMELUZ, carefully wipe all lesions (sBCC or AK) with an ethanol or isopropanol-soaked cotton pad to ensure degreasing of the skin.

Figure 1A: Degreasing the skin

Thereafter, remove any scaling and crusts and gently roughen all lesion surfaces, taking care to avoid bleeding.

Figure 1B: Removal of scales and crusts (debridement)

Step 2. Application of AMELUZ

Apply AMELUZ using glove protected fingertips or a spatula. Use enough AMELUZ to cover individual lesions (sBCC or AK) or the entire AK field:

Lesion-directed AK treatment: Apply AMELUZ approximately 1 mm thick to one or more individual AK lesions and include approximately 5 mm of the surrounding healthy skin.

Field-directed AK treatment: Apply AMELUZ approximately 1 mm thick to the treatment field. Apply AMELUZ to the lesions and the skin between the lesions. Additionally, cover at least 5 mm of the surrounding healthy area. …

How to take Aminolevulinic Acid — instructions & advice from the label

Inform patients and their caregivers that AMELUZ may cause hypersensitivity, potentially including severe cases (anaphylaxis) .

Inform patients that transient amnestic episodes have been reported with use of AMELUZ in combination with photodynamic therapy. Advise patients and their families or caregivers to contact their healthcare provider if memory impairment, confusion, or disorientation is observed .

Advise patients that following treatment with AMELUZ, avoid exposure to sunlight, and prolonged or intense light on the treated lesion sites and surrounding skin for approximately 48 hours.

Advise patients to avoid certain medications that may enhance the phototoxic reaction to PDT .

Inform patients that sensations of burning and pain that may be severe commonly occur during and after treatment with AMELUZ in combination with PDT. Advise patients to contact the healthcare provider if symptoms are severe .

Inform patients that treatment with AMELUZ in combination with PDT may result in adverse reactions which include local skin reactions at the application site such as erythema, pain/burning, irritation, edema, pruritus, exfoliation, induration, scab, and vesicles .

Warnings & precautions

Do not take this medicine if: AMELUZ is contraindicated in patients with:

Known hypersensitivity to porphyrins.

Known hypersensitivity to any of the components of AMELUZ, which includes soybean phosphatidylcholine .

Porphyria. AMELUZ use may cause uncontrolled phototoxic effects .

Photodermatoses. PDT may worsen the phototoxic or photoallergic reactions .

Several cases of hypersensitivity were reported during postmarketing use of AMELUZ prior to PDT illumination . If hypersensitivity reactions occur, clean the area of skin where AMELUZ was applied and institute appropriate therapy. Inform patients and their caregivers that AMELUZ may cause hypersensitivity, potentially including severe cases (anaphylaxis).

Transient amnestic episodes have been reported during postmarketing use of AMELUZ in combination with PDT. Inform patients and their caregivers that AMELUZ in combination with PDT may cause transient amnestic episodes. Advise them to contact the healthcare provider if the patient develops amnesia after treatment.

BF-RhodoLED or RhodoLED XL lamp may cause eye irritation, glare, vision blurred, visual impairment or injury. Before operating the lamp, personnel must refer to the user manual for specific warnings, cautions, and instructions. Eye exposure to the BF-RhodoLED or RhodoLED XL light must be prevented. Protective eye equipment must be used by patients, healthcare providers, and any person present during the illumination period. Avoid staring directly into the light source.

Eyelid edema and dry eyes have occurred after PDT with AMELUZ. PDT with AMELUZ can cause ophthalmic adverse reactions. Avoid direct contact of AMELUZ with the eyes. Rinse eyes with water in case of accidental contact.

AMELUZ increases photosensitivity. …

Aminolevulinic Acid side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

​Hypersensitivity .

Transient Amnestic Episodes .

Risk of BF-RhodoLED or RhodoLED XL Lamp Induced Eye Injury .

Ophthalmic Adverse Reactions .

Increased Photosensitivity .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Subjects with Mild-to-Moderate Actinic Keratosis

The safety and efficacy of AMELUZ in combination with PDT using a narrow spectrum source was evaluated in three double-blind and placebo-controlled phase 3 trials (Trials 1, 2, and 3), enrolling a total of 299 subjects that were treated with narrow band light. Trial subjects were adults greater than or equal to 49 years of age, and the majority had Fitzpatrick skin type I, II, or III. No subjects had Fitzpatrick skin type V or VI. Approximately 86% of subjects were male, and all subjects were White .

For all three trials, the enrolled subjects had mild to moderate AKs (Olsen grade 1 and 2) with 4 to 8 lesions on the face and scalp. Overall, 212 AMELUZ-treated subjects (n=32, n=55, and n=125) and 87 subjects receiving placebo (n=16, n=32, n=39) were illuminated with BF-RhodoLED or similar narrow spectrum lamps. …

Drug interactions

There have been no formal studies of the interaction of AMELUZ with other drugs. It is possible that concomitant use of other known photosensitizing drugs, such as St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines, may enhance the phototoxic reaction to PDT .

About this medicine

AMELUZ (aminolevulinic acid hydrochloride) topical gel, 10% is a non-sterile white-to-yellowish gel. The gel formulation contains a nanoemulsion.

Aminolevulinic acid, a porphyrin precursor, is a white to off-white crystalline solid. It is readily soluble in water, methanol, and dimethylformamide. Its chemical name is 5-amino-4-oxo-pentanoic acid hydrochloride, molecular weight is 167.59 and molecular formula is C5H9NO3·HCl. The structural formula of aminolevulinic acid hydrochloride is represented below:

Each gram of AMELUZ contains 100 mg of aminolevulinic acid hydrochloride (equivalent to 78 mg aminolevulinic acid) as the active ingredient and the following inactive ingredients: xanthan gum, soybean phosphatidylcholine, polysorbate 80, medium-chain triglycerides, isopropyl alcohol, dibasic sodium phosphate, monobasic sodium phosphate, sodium benzoate and purified water.

How it works: Photoactivation following topical application of AMELUZ occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX (PpIX), a photoactive compound which accumulates in the skin. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 650daa9f-aeec-49ce-95b9-5fa20b988afd. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate